Thylacine Biotherapeutics Inc — Form D

Thylacine Biotherapeutics Inc of MIAMI BEACH, FL, a company, filed a Form D exempt-offering notice with the SEC on 2023-01-19. The offering totals $1.0M, of which $476K was reported sold. Industry: Biotechnology.

Offering

• Filed: 2023-01-19
• Form: D
• Accession: 0001962783-23-000001
• Industry: Biotechnology
• Exemptions: 06b
• Total offering: $1.0M
• Amount sold: $476K
• Remaining: $524K
• Minimum investment: $5K
• Investors: 13
• Date of first sale: 2023-01-05
• Security types: equity, debt
• Revenue range: No Revenues
• SEC file number: 021-471173

Issuer

• Name: Thylacine Biotherapeutics Inc
• CIK: 0001962783
• Entity type: Corporation
• Jurisdiction: DELAWARE
• Incorporated: 2021
• Address: 6899 COLLINS AVE, MIAMI BEACH, FL, 33141
• Phone: 6503021392

Officers, directors & promoters (4)

More

• CIK 1962783 on SEC EDGAR (source of record)
• This page as markdown (for LLM agents)
• Search all SEC filings, advisers and people on Adviser Search